Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2176 to 2190 of 8218 results

  1. Tucatinib with trastuzumab emtansine for treating HER2-positive unresectable or advanced breast cancer after a taxane, trastuzumab or both together [TSID11781]

    Awaiting development Reference number: GID-TA11110 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Tocilizumab for treating systemic sclerosis [ID1396]

    Awaiting development Reference number: GID-TA10346 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Tiratricol for treating Allan–Herndon–Dudley syndrome [ID6217]

    Awaiting development Reference number: GID-TA11192 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Tislelizumab for untreated unresectable hepatocellular carcinoma [TSID10683]

    Awaiting development Reference number: GID-TA11053 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. STS101 for treating acute migraine [TSID11782]

    Awaiting development Reference number: GID-TA11147 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Subcutaneous efgartigmod with recombinant human hyaluronidase PH20 for treating primary immune thrombocytopenia [TSID11977]

    Awaiting development Reference number: GID-TA11507 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Talazoparib with enzalutamide for untreated hormone-sensitive metastatic prostate cancer with a homologous recombination repair mutation [ID6460]

    Awaiting development Reference number: GID-TA11534 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Lenacapavir for treating multidrug resistant HIV-1 [ID6196]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  9. Letermovir for preventing cytomegalovirus infection in people under 18 years after allogeneic haematopoietic stem cell transplant [TS ID 11868]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  10. Eneboparatide for treating chronic hypoparathyroidism [TSID12145]

    Awaiting development Reference number: GID-TA11713 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Nivolumab with ipilimumab for adjuvant treatment of localised renal cell carcinoma [TSID9659]

    Awaiting development Reference number: GID-TA11111 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Imbio CT lung texture analysis for identifying interstitial lung disease (MT618) (MIB272)

    Topic prioritisation

    Diagnostics guidance
    Topic prioritisation

  13. Dupilumab for treating eosinophilic oesophagitis in children 1 to 11 years [ID6492]

    Awaiting development Reference number: GID-TA11383 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Atezolizumab with cabozantinib for treating metastatic non-small-cell lung cancer after platinum-based chemotherapy and 1 PD-L1 checkpoint inhibitor TSID 11812

    Topic prioritisation

    Health technology evaluations
    Topic prioritisation

  15. Pegargiminase with pemetrexed and cisplatin for untreated advanced malignant pleural mesothelioma [ID1575]

    Awaiting development Reference number: GID-TA10486 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development